|
|
Volumn 3, Issue 4, 2005, Pages 205-206
|
|
Warfarin initiation and the potential role of genomic-guided dosing.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTICOAGULANT AGENT;
CYP2C9 PROTEIN, HUMAN;
UNSPECIFIC MONOOXYGENASE;
VITAMIN K GROUP;
WARFARIN;
GENETICS;
GENOME;
HUMAN;
INTERNATIONAL NORMALIZED RATIO;
METABOLISM;
METHODOLOGY;
NOTE;
PHARMACOGENETICS;
TREATMENT OUTCOME;
ANTICOAGULANTS;
ARYL HYDROCARBON HYDROXYLASES;
GENOME;
HUMANS;
INTERNATIONAL NORMALIZED RATIO;
PHARMACOGENETICS;
TREATMENT OUTCOME;
VITAMIN K;
WARFARIN;
|
|
EID: 34548107013
PISSN: 15394182
EISSN: None
Source Type: Journal
DOI: 10.3121/cmr.3.4.205 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
